Shopping Cart
- Remove All
Your shopping cart is currently empty
Befetupitant
Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.
Catalog No. T14524Cas No. 290296-68-3
Select Batch
Purity:98.67%
Contact us for more batch information
Befetupitant
Catalog No. T14524Cas No. 290296-68-3
Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $490 | In Stock | |
| 5 mg | $1,070 | In Stock | |
| 10 mg | $1,300 | In Stock | |
| 25 mg | $1,715 | In Stock | |
| 50 mg | $2,180 | In Stock | |
| 100 mg | $2,800 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Befetupitant"
Aprepitant
T1743170729-80-3
Aprepitant is a Substance P/Neurokinin-1 Receptor Antagonist. The mechanism of action of aprepitant is as a Neurokinin 1 Antagonist, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 3A4 Inducer.
- $48
Size
QTY
Maropitant
T7209147116-67-4
Maropitant is a selective neurokinin (NK1) receptor antagonist.
- $43
Size
QTY
Rolapitant
T3716552292-08-7
Rolapitant (SCH619734) Hydrochloride is the hydrochloride salt form of rolapitant, an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. Compared to other NK1-receptor antagonists, rolapitant has both a more rapid onset of action and a much longer half-life.
- $43
Size
QTY
N-Acetyl-L-tryptophan
T87891218-34-4
N-Acetyl-L-tryptophan (N-acetyltryptophan) is an inhibitor of neurokinin 1 receptor (NK1-receptor, NK1R).
- $30
Size
QTY
Fosaprepitant dimeglumine
T1790265121-04-8
Fosaprepitant dimeglumine (MK-0517) is the dimeglumine salt form of fosaprepitant, a water-soluble, N-phosphorylated prodrug of aprepitant with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent selectively binds to human substance P/neurokinin 1 (NK1) receptors in the central nervous system (CNS), inhibiting receptor binding of endogenous substance P and preventing substance P-induced emesis.
- $45
Size
QTY
Ezlopitant
T68068147116-64-1In house
Ezlopitant (CJ-11974) is a small molecule neurokinin-1-receptor (NK1) antagonist used to treat nausea, vomiting and pain.
- $85
Size
QTY
(R)-CJ 11974
T68068L187281-35-2In house
(R)-CJ 11974 is a novel non-peptide neurokinin NK1 substance P receptor antagonist with potential analgesic activity that can be used to study chemotherapy-induced vomiting.
- $195
Size
QTY
Netupitant
T6905290297-26-6
Netupitant (CID 6451149) is a specific neurokinin 1 (NK1) receptor antagonist (Ki: 0.95 nM).
- $47
Size
QTY
Vofopitant
T13329168266-90-8In house
Vofopitant (GR 205171) is a potent NK1 receptor antagonist with anxiolytic and antiemetic activity for the study of post-traumatic stress disorder (PTSD).
- $100
Size
QTY
Lanepitant 2HCl
T25616170508-05-1In house
Lanepitant 2HCl is a non-peptide neurokinin-1 receptor antagonist with analgesic and anti-inflammatory activity.Lanepitant 2HCl inhibits the binding of Substance P to the neurokinin-1 receptor, inhibits neurogenic inflammation and pain transmission, and can be used in the study of painful neuropathic disorders, such as migraines.
- $195
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Befetupitant (Ro67-5930) is a potent and selective tachykinin 1 receptor (NK1R) antagonist for the study of corneal neovascularization. |
| In vivo | In the alkali burn model, Befetupitant, a highly selective NK1R antagonist, was tested. Hemangiogenesis and lymphangiogenesis were effectively reduced (P<0.05) after topical application of Befetupitant for 4 days at both concentrations (0.4 and 1.6 mg/mL). However, both Befetupitant and its vehicle DMSO induced corneal opacity even in healthy controls, as observed during slit-lamp examination. Furthermore, fluorescein and hematoxylin-eosin staining confirmed DMSO toxicity by revealing epithelial damage and inflammatory cellular infiltration in the stroma. Despite Befetupitant's effectiveness in reducing corneal neovascularization (CNV) in the alkali burn model, its toxicity due to the DMSO vehicle led to the decision not to test it in the suture model[1]. |
| Alias | Ro67-5930 |
| Molecular Weight | 565.55 |
| Formula | C29H29F6N3O2 |
| Cas No. | 290296-68-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 6.88 mg/mL (12.16 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Befetupitant | purchase Befetupitant | Befetupitant cost | order Befetupitant | Befetupitant chemical structure | Befetupitant in vivo | Befetupitant formula | Befetupitant molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.